[
  {
    "ts": "2026-02-27T00:30:02+00:00",
    "headline": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
    "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
    "url": "https://www.barchart.com/story/news/457469/love-dividends-1-stock-to-buy-now-with-a-yield-over-6",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "5d1714c1-838c-330c-8f72-1f04a85bf9b1",
      "content": {
        "id": "5d1714c1-838c-330c-8f72-1f04a85bf9b1",
        "contentType": "STORY",
        "title": "Love Dividends? 1 Stock to Buy Now With a Yield Over 6%.",
        "description": "",
        "summary": "Even amid volatility, Pfizer keeps rewarding shareholders year after year.",
        "pubDate": "2026-02-27T00:30:02Z",
        "displayTime": "2026-02-27T00:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82",
          "originalWidth": 1600,
          "originalHeight": 1054,
          "caption": "Money bag with the word Dividends by Andrii Yalanskyi via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8AbXQLuHyuWf6J2NZjhbww--~B/aD0xMDU0O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 1600,
              "height": 1054,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ljd0Jvh1WDKM3R0BdHhrVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/7a001c013d6478f36b63c9346edbba82.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/457469/love-dividends-1-stock-to-buy-now-with-a-yield-over-6",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/love-dividends-1-stock-buy-003002196.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T05:07:26+00:00",
    "headline": "Novavax Q4 Earnings Call Highlights",
    "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
    "url": "https://www.marketbeat.com/instant-alerts/novavax-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "73442ed1-fe48-3d25-a4ff-d149dc7ecdb0",
      "content": {
        "id": "73442ed1-fe48-3d25-a4ff-d149dc7ecdb0",
        "contentType": "STORY",
        "title": "Novavax Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Novavax (NASDAQ:NVAX) executives told investors the company made “significant progress” in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balan",
        "pubDate": "2026-02-27T05:07:26Z",
        "displayTime": "2026-02-27T05:07:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Novavax logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hTdY6eLQqsZjWYovkoWMAQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ls57TlEE2kRGYbXTMhEumA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/06036d4683227ebf91b1ff6c594a32af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/novavax-q4-earnings-call-highlights-2026-02-26/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novavax-q4-earnings-call-highlights-050726500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVAX"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-27T12:01:44+00:00",
    "headline": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "c2023d61-9bd2-366b-8986-5429356ab5db",
      "content": {
        "id": "c2023d61-9bd2-366b-8986-5429356ab5db",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the most undervalued stocks under $30 to buy. On February 24, the US FDA granted full approval to Pfizer’s BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for the first-line treatment of adults with BRAF V600E-mutant metastatic colorectal cancer/mCRC. This decision converts a previous accelerated approval into a […]",
        "pubDate": "2026-02-27T12:01:44Z",
        "displayTime": "2026-02-27T12:01:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b",
          "originalWidth": 640,
          "originalHeight": 427,
          "caption": "Pfizer (PFE) Secures Full FDA Approval for BRAFTOVI as First-Line Treatment in mCRC",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CncPfS_Mqj5tx.LtSIbZSQ--~B/aD00Mjc7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 640,
              "height": 427,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kTdkjgY5eFmOS7TjNI_NNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ad5ab9008999bda323a107790a6dab9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-secures-full-fda-120144586.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]